Adial shareholders approve authorized share increase, reverse split, and equity plan amendment at 2025 annual meeting

ADIAL PHARMACEUTICALS, INC.

Approved increase in authorized common stock from 50M to 100M shares, effective August 1, 2025.
Approved reverse stock split at a ratio of 1-for-2 to 1-for-25, with ratio set by Board.
Approved Amendment No. 7 to 2017 Equity Plan, increasing reserved shares from 2M to 5M.
Approved issuance of up to 6.73M shares upon exercise of Series B-1/C-1 warrants from May 2025 offering.
Approved issuance of up to 19.425M shares upon exercise of Series D/E warrants from June 2025 offering.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

ADIAL PHARMACEUTICALS, INC.: Amendment to Certificate of Incorporation to increase authorized shares of Common Stock from 50,000,000 to 100,000,000 (effective 2025-08-01).

Change: charter amendment
Effective: 2025-08-01

Exact text from the filing

On August 1, 2025, the Company’s stockholders approved a proposal at the Annual Meeting to amend the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), at the discretion of our Board, to increase to the authorized number of shares of the Company’s Common Stock, from 50,000,000 to 100,000,000 (the “Authorized Increase”). Following such approval and the approval of the Board at a meeting of the Board held on August 1, 2025, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Authorized Increase, with an effective time of 4:00 p.m. Eastern Time on August 1, 2025.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-070642

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.